<i id='F1411BFC5A'><strike id='F1411BFC5A'><tt id='F1411BFC5A'><pre id='F1411BFC5A'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop
read more
ChristineKao/STATAfterearningherdoctorateincellbiologyattheUniversityofPennsylvaniainJune,SierraColl
read more
AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge
read moreChristineKao/STATAfterearningherdoctorateincellbiologyattheUniversityofPennsylvaniainJune,SierraColl
